Immunotherapy drug improves outcomes for some children with relapsed leukemia
- OPACC
- Dec 11, 2019
- 1 min read
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.
Commenti